Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pharmacokinetic Phase 1 Study of Anti-epidermal Growth Factor Receptor (EGFR) -Immunoliposomes Loaded With Doxorubicin in Patients With Relapsed or Refractory High-grade Gliomas

NCT03603379 is registered in ClinicalTrials.gov with University Hospital, Basel, Switzerland as lead sponsor.

NCT NCT03603379
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03603379 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pharmacokinetic Phase 1 Study of Anti-epidermal Growth Factor Receptor (EGFR) -Immunoliposomes Loaded With Doxorubicin in Patients With Relapsed or Refractory High-grade Gliomas
Lead sponsor
University Hospital, Basel, Switzerland
Phase
Phase 1
Overall status
Completed
Start date
November 16, 2018
Completion date
November 1, 2020
Enrollment
9 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

glioblastoma